Lung Transplantation: Clinical Trials

12 trials for Lung Transplantation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 2 unknown, 1 not yet recruiting. 12 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 7, Recruiting 2, Unknown 2, Not yet recruiting 1
Phase 32Completed 1, Unknown 1

Follow Lung Transplantation: new trials by email Literature Review of Lung Transplantation trials Research Report on Lung Transplantation

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Low-Frequency rTMS for In-Hospital Sleep Disturbance After Lung Transplantation
Active Low-Frequency Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation - Sleep Wake Disorders, Lung Transplantation
Phase 2Not yet recruitingThe First Affiliated Hospital of Guangzhou Medical University1522026-08-312026-09-01
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Maraviroc, Placebo - Primary Graft Dysfunction, Lung Transplantation
Phase 2RecruitingUniversity of California, San Francisco1202025-12-072026-01-20
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
LAM-001, Placebo - Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction
Phase 2RecruitingSteven Hays, MD302023-08-172026-05-18
Naloxone for Optimizing Hypoxemia Of Lung Donors
Naloxone, Normal saline - Brain Death, Organ Donors
Phase 2 / Phase 3CompletedWashington University School of Medicine1992015-09-012020-07-31
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
Alpha -1 Antitrypsin, Alpha-1 Antitrypsin, AAT - Lung Transplantation, Bronchiolitis Obliterable Syndrome
Phase 2UnknownRabin Medical Center402011-09-012011-07-14
Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®
Advagraf, Prograf - Heart Transplantation, Lung Transplantation
Phase 2CompletedAstellas Pharma Inc172011-07-012015-06-16
Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education
Patient education - Lung Transplantation
Phase 2CompletedHannover Medical School642011-07-012013-06-06
Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®
Tacrolimus, Tacrolimus prolonged release - Intestine Transplantation, Kidney Transplantation
Phase 2CompletedAstellas Pharma Europe Ltd.812011-05-252026-10-19
Intravenous Immunoglobulin (IVIG) in Lung Transplantation
IVIG, Placebo - Hypogammaglobulinemia, Lung Transplantation
Phase 2CompletedColumbia University112005-06-012019-03-05
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Repertaxin, Placebo - Ischemia-Reperfusion Injury, Lung Transplantation
Phase 2CompletedDompé Farmaceutici S.p.A1142005-05-012024-12-11
Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation
Nitric oxide - Lung Transplantation
Phase 2CompletedMallinckrodt492005-04-012016-10-19
The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study
Surfactant (calfactant) - Lung Transplantation, Primary Graft Dysfunction
Phase 2 / Phase 3UnknownRabin Medical Center422005-01-012007-07-25

Narrower conditions

Primary Graft Dysfunction (2)  ·  Acute Lung Injury (1)  ·  Agammaglobulinemia (1)  ·  Brain Death (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Reperfusion Injury (1)  ·  Sleep Wake Disorders (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (5)  ·  Pathologic Processes (4)  ·  Cardiovascular Diseases (3)  ·  Postoperative Complications (3)  ·  Vascular Diseases (3)  ·  Immune System Diseases (2)  ·  Lung Diseases (2)  ·  Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Reperfusion Injury (2)  ·  Respiratory Tract Diseases (2)  ·  Blood Protein Disorders (1)  ·  Brain Diseases (1)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)

Interventions

Tacrolimus (2)  ·  Immunoglobulins, Intravenous (1)  ·  Maraviroc (1)  ·  Naloxone (1)  ·  Nitric Oxide (1)  ·  Patient Education as Topic (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Surface-Active Agents (1)  ·  alpha 1-Antitrypsin (1)  ·  calfactant (1)  ·  gamma-Globulins (1)  ·  reparixin (1)

Sponsors

Rabin Medical Center (2)  ·  Astellas Pharma Europe Ltd. (1)  ·  Astellas Pharma Inc (1)  ·  Columbia University (1)  ·  Dompé Farmaceutici S.p.A (1)  ·  Hannover Medical School (1)  ·  Mallinckrodt (1)  ·  Steven Hays, MD (1)  ·  The First Affiliated Hospital of Guangzhou Medical University (1)  ·  University of California, San Francisco (1)  ·  Washington University School of Medicine (1)

Countries

United States (5)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Israel (1)  ·  Poland (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Daniel Calabrese, MD (1)  ·  Jens T Gottlieb, MD (1)  ·  MordechaI R Kramer, Prof (1)  ·  Mordechai R Kramer, M.D (1)  ·  Rajat Dhar, MD (1)  ·  Roberto Novellini, MD (1)  ·  Rosario Vicente, MD (1)  ·  Selim M Arcasoy, M.D. (1)  ·  Steven Hays, MD (1)

Results publications

PMID 24608864, PMID 25090414, PMID 30399122, PMID 36094829